> ## Content Index
> Fetch the complete content index at: https://www.foodconsumer.org/llms.txt
> Use this file to discover other available public pages before exploring further.

# Nexavar Falls Short of Goal
- URL: https://www.foodconsumer.org/nexavar_falls_short_of_goal_0614101016/
- Published: 2010-06-14T11:12:00.000Z
- Updated: 2026-09-22T16:07:15.000Z
- Description: Bayer says Nexavar missed its main goal of extending survival in a trial of advanced lung cancer, though it met a secondary goal of slowing progression. The drug is already approved for late-stage kidney and liver cancer, and testing continues in other cancers.
- Author: Rachel Stockton
- Tags: Cancer, Avoiding Illness, #vivvo-import

Bayer AG, the pharmaceutical company that manufactures Nexavar, announced that in clinical trials, the drug failed to reach its goal of extending the lives of patients with a certain type of advanced lung cancer.

Nexavar has already garnered approval in patients with late stage kidney and liver cancer. And, in the most recent trial, the drug did reach its secondary goal of preventing late stage lung cancer from getting worse.

Nexavar works by stopping new blood vessels that feed cancer cells from being formed; in the clinical trial, the drug was used in tandem with chemotherapy and compared to a placebo. The company asserts they will keep testing the drug in lung cancer patients, both in combination with other drugs, and on its own. The drug is also being tested in patients with ovarian, colon, thyroid and breast cancer.

In other lung cancer news, scientists trying to determine why lung cancer has been increasing among women say that estrogen likely plays a role, especially in women who have never smoked but have gotten the disease, nonetheless. According to the American Cancer Society, smoking is thought to be related to 87% of all lung cancer.